kabutan

RaQualia Pharma Inc.(4579) Summary

4579
TSE Growth
RaQualia Pharma Inc.
1,020
JPY
+36
(+3.66%)
Jan 29, 3:11 pm JST
6.65
USD
Jan 29, 1:12 am EST
Result
PTS
outside of trading hours
1,017.1
Jan 29, 3:10 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.16
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
970 JPY 6.33 USD
Previous Close Jan 28
984 JPY 6.44 USD
High Jan 29, 3:05 pm
1,020 JPY 6.66 USD
Low Jan 29, 9:15 am
967 JPY 6.31 USD
Volume
331,600
Trading Value
0.33B JPY 2.16M USD
VWAP
994.66 JPY 6.5 USD
Minimum Trading Value
102,000 JPY 665 USD
Market Cap
0.02T JPY 0.16B USD
Number of Trades
1,110
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
1,324
1-Year High Dec 2, 2025
41,024
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 3,328,400
Jan 16, 2026 1,000 3,118,400 3118.40
Jan 9, 2026 700 3,021,300 4316.14
Dec 26, 2025 200 2,793,300 13966.50
Dec 19, 2025 1,200 2,873,100 2394.25
Company Profile
RaQualia Pharma Inc. is a drug discovery venture company specializing in pain disorders. Its main revenue source is the out-licensing of intellectual property rights for drug candidates.
Sector
Pharmaceuticals
RaQualia Pharma Inc. is a research and development-oriented drug discovery venture with a business model focused on out-licensing intellectual property rights of novel drug candidates to pharmaceutical companies. The company conducts drug discovery research and development for high-need medical conditions, primarily in gastrointestinal and pain disorders. RaQualia Pharma Inc. pursues agile and flexible business activities, offering its entire research and development portfolio for out-licensing at various stages, from early exploration to clinical development. The company actively engages in open innovation-based research and development, addressing a wide range of disease areas through industry-academic collaborations. RaQualia Pharma Inc. has built a research and development portfolio comprising multiple projects, including out-licensing preparation programs, out-licensed programs, and collaborative research programs.